(5-Oxooxan-3-yl)carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (5-Oxooxan-3-yl)carbamic acid
• 英文别名: (5-oxooxan-3-yl)carbamic acid
• 化学式: C₆H₉NO₄
• 分子量: 159.14
• InChiKey: NPCZVMOQPCVEPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSÉS DE CARBAMOYLPYRIDONE POLYCYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：GILEAD SCIENCES INC

  公开号：WO2014100323A1

  公开（公告）日：2014-06-26

  Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  披露了用于治疗人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下式（I）：包括立体异构体和其药用可接受的盐，其中R1、X、W、Y1、Y2、Ζ1和Z4如本文所定义。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
  申请人：Gilead Sciences, Inc.

  公开号：US20140221356A1

  公开（公告）日：2014-08-07

  Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明揭示了用于治疗人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下式子（I）：包括立体异构体和其药学上可接受的盐，其中R1、X、W、Y1、Y2、Z1和Z4的定义如本文所述。本发明还揭示了与制备和使用这些化合物相关的方法，以及包含这些化合物的制药组合物。
• SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS
  申请人：Gilead Sciences, Inc.

  公开号：US20160176885A1

  公开（公告）日：2016-06-23

  Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , X, W, Y 1 , Y 2 , Z 1 , and Z 4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明揭示了用于治疗人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下式（I）：包括立体异构体和其药学上可接受的盐，其中R1、X、W、Y1、Y2、Z1和Z4如本文所定义。本发明还揭示了与制备和使用这些化合物相关的方法，以及包含这些化合物的制药组合物。
• [EN] PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE BTK
  申请人：BIOGEN MA INC

  公开号：WO2022104079A1

  公开（公告）日：2022-05-19

  Provided are compounds of Formula (I'): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

  提供了公式（I'）的化合物或其药学上可接受的盐，其中公式中的变量如此处定义；以及它们的使用和生产方法。
• Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
  申请人：Gilead Sciences, Inc.

  公开号：US10035809B2

  公开（公告）日：2018-07-31

  Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本研究公开了用于治疗人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有下式 (I)： 包括其立体异构体和药学上可接受的盐类，其中 R1、X、W、Y1、Y2、Z1 和 Z4 如本文所定义。此外，还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。